← Leaderboards
David Beasley
University Of Texas Med Br Galveston
$17,578,609
Attributed
$17,578,609
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.9M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,578,609 · 2
By mechanism
N01$17,578,609 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Alexander Bukreyev$20,278,136
- Jens Meiler$20,483,777
- Alexander Niclas Freiberg$3,141,620
- Gustavo Valbuena$2,885,920
- Junki Maruyama$675,217
Others in their field
Other Emerging Leaders on “Contracts”
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lynn Briscoe · Leidos Biomedical Research, Inc.$236,279,699
- Leonard Freedmand · Leidos Biomedical Research, Inc.$165,274,216
- Kimberly Smith · Ppd Development Lp$116,584,264
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$95,500,810
Research focus
ContractsInfectious Disease ModelAnimal ModelStandardizationEfficacy TestingLicensureEvaluationAnimal Model DevelopmentBasic Science2019-NcovLungTherapeutic DevelopmentTherapeutic EvaluationMicrophysiology SystemCovid-19Virus DiseasesMedical CountermeasureFilovirusAnimalsScreeningVaccinesLung DevelopmentMouse ModelPathogen
Grant awards (26)
TASK A11: MODELS FOR CYTOMEGALOVIRUS AND HERPES SIMPLEX VIRUSES$1,162,419
N01 · FY2025 · AI · contact PI
Task A90: Establishment of a Model of Nipah Virus Infection for Assessment of Medical Countermeasures Efficacy$382,402
N01 · FY2025 · AI · contact PI
Task A02: Development of Small Animal Lassa Virus infection Model for the Assessment of Anti-Viral Activity of Medical Countermeasures Efficacy$151,805
N01 · FY2025 · AI · contact PI
Task A02: Development of Small Animal Lassa Virus infection Model for the Assessment of Anti-Viral Activity of Medical Countermeasures Efficacy$1,010,897
N01 · FY2024 · AI · contact PI
Task A63: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus$849,562
N01 · FY2024 · AI · contact PI
Task A90: Establishment of a Small Animal Model of Nipah Virus (NiV) Infection for Assessment of Medical Countermeasures Efficacy$817,451
N01 · FY2024 · AI · contact PI
Task C14: Advancing Human Lung Microphysiological Systems to Model Coronavirus Infection and Test Candidate Countermeasures$420,758
N01 · FY2024 · AI · contact PI
Task C14: Advancing Human Lung Microphysiological Systems to Model Coronavirus Infection and Test Candidate Countermeasures$319,313
N01 · FY2024 · AI · contact PI
Task A06: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms$174,528
N01 · FY2024 · AI · contact PI
Task A66: Rodent Models for Testing Therapeutics Against Filoviruses$4,250
N01 · FY2024 · AI · contact PI
Task A63: Evaluation of therapeutics and vaccines in mouse models of dengue virus$825,058
N01 · FY2023 · AI · contact PI
Task A66: Rodent models for testing therapeutics against filoviruses$335,518
N01 · FY2023 · AI · contact PI
Task A63: Evaluation of therapeutics and vaccines in mouse models of dengue virus$1,001,923
N01 · FY2022 · AI · contact PI
TASK A72: EFFICACY TESTING OF BACTERIOPHAGE COCKTAIL AGAINST YERSINIA PESTIS$660,074
N01 · FY2022 · AI · contact PI
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)$575,498
N01 · FY2022 · AI · contact PI
Task A66: Rodent models for testing therapeutics against filoviruses$472,205
N01 · FY2022 · AI · contact PI
Task C11: Using a Human Lung Microphysiologic System to Model SARS-CoV-2 Infection and Test Candidate Countermeasures$430,965
N01 · FY2022 · AI · contact PI
Task B13: Evaluation of MCMs directed against BSL-4 Viruses in Non-Human Primates (NHPs)$978,859
N01 · FY2021 · AI · contact PI
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)$631,416
N01 · FY2021 · AI · contact PI
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)$631,415
N01 · FY2021 · AI · contact PI
Task C06: Lung Microphysiological Systems as Models of Infectious Diseases for BSL-3 Pathogens$391,133
N01 · FY2021 · AI · contact PI
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)$646,787
N01 · FY2020 · AI · contact PI
Task C06: Lung Microphysiological Systems as Models of Infectious Diseases for BSL-3 Pathogens$400,432
N01 · FY2020 · AI · contact PI
Task C06: Lung Microphysiological Systems as Models of Infectious Diseases for BSL-3 Pathogens$388,097
N01 · FY2019 · AI · contact PI
Task B06: Development and refinement of non-human primate models for medical countermeasure evaluation of BSL-4 viruses$3,465,763
N01 · FY2018 · AI · contact PI
Task A12: Testing teixobactin in rabbit model of inhalational anthrax$450,081
N01 · FY2018 · AI · contact PI